FGF19 and metabolic dysfunction-associated steatotic liver disease: Additionally, it has been demonstrated that the reduction in fibroblast growth factor 19 (FGF-19) levels in patients with cholecystectomy can increase liver triglyceride content, potentially influencing the development of NAFLD.17 This study is one of the few that compares liver fibrosis using elastography in patients with NAFLD, both with and without a history of cholecystectomy.